Bristol-Myers Squibb
This article was originally published in The Tan Sheet
Executive Summary
Restructuring and realignment plan announced Jan. 4 includes a reduction of employee levels by "approximately 5,000" worldwide "during the next two years." The company noted that "four Bristol- Myers Squibb core businesses" -- consumer products, nutritionals, pharmaceuticals and medical devices -- and "headquarters staff will be affected." Most of the staff cuts will be in BMS' prescription Pharmaceutical Group, which will be reorganized into 12 regional business units in the U.S. Eleven business units will be formed in Europe covering all BMS product categories
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning